Apatinib mesylate tablet

DRUG4 trials

Sponsors

Chinese Academy of Medical Sciences, Guilin Medical University, China, Wei Jiang

Conditions

Nasopharyngeal CarcinomaSmall Cell Lung Cancer

Phase 2

Study of Apatinib as Third-line and Later Therapy in Patients With Small Cell Lung Cancer (SCLC)

Chinese Academy of Medical SciencesSmall Cell Lung Cancer

Start: 2016-12-31End: 2018-09-30Target: 25Updated: 2017-09-07

Maintenance Treatment of Apatinib in Nasopharyngeal Carcinoma

Guilin Medical University, ChinaNasopharyngeal Carcinoma

Start: 2017-01-01End: 2019-12-08Updated: 2018-05-16

Adjuvant Treatment of Apatinib in Nasopharyngeal Carcinoma

Wei JiangNasopharyngeal Carcinoma

Start: 2018-07-01End: 2021-07-28Target: 240Updated: 2018-08-02

Apatinib Combined With PD-1 in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

CompletedNCT04350190

Wei JiangNasopharyngeal Carcinoma

Start: 2021-01-14End: 2022-09-15Updated: 2023-01-13

Related Papers

Adjuvant apatinib following concurrent chemoradiotherapy in high-risk nasopharyngeal carcinoma: A multicenter, prospective, phase 2 study.

Journal of Clinical Oncology2025-05-28

Apatinib combined with camrelizumab in the treatment of recurrent/metastatic nasopharyngeal carcinoma: a prospective multicenter phase II study

Frontiers in Immunology2024-01-037 citations

Camrelizumab plus apatinib in patients with recurrent and/or metastatic nasopharyngeal carcinoma: A single-arm, multicenter, phase 2 trail.

Journal of Clinical Oncology2022-06-01

Apatinib for the treatment of metastatic or locoregionally recurrent nasopharyngeal carcinoma after failure of chemotherapy: A multicenter, single‐arm, prospective phase 2 study

Cancer2021-05-2735 citations

A Prospective Study of Apatinib in Patients with Extensive-Stage Small Cell Lung Cancer After Failure of Two or More Lines of Chemotherapy

The Oncologist2020-04-0624 citations

Apatinib for locoregionally recurrent or metastatic nasopharyngeal carcinoma after failure of first-line chemotherapy: A multicenter, phase II trial.

Journal of Clinical Oncology2019-05-202 citations

Efficacy and safety of apatinib in extensive stage small cell lung cancer patients failed from two or more lines of chemotherapy.

Journal of Clinical Oncology2019-05-202 citations